Interactions between Clevidipine and Titralac

The calcium carbonate in Titralac has a major potential interaction with Achlorhydria.

Calcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.

Clevidipine has a major potential interaction with Aortic Stenosis.

Clevidipine is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery.

The calcium carbonate in Titralac has a major potential interaction with Arrhythmia.

Calcium is involved in cardiac muscle contraction and electrical impulse conduction. Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease. Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias. Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.

Clevidipine has a moderate potential interaction with Heart Failure.

The use of clevidipine can produce negative inotropic effects and exacerbate heart failure. It is recommended to monitor heart failure patients carefully during treatment with this agent.

Clevidipine has a major potential interaction with High Cholesterol.

Clevidipine is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.

Clevidipine has a moderate potential interaction with Hypotension.

The use of clevidipine may produce systemic hypotension and reflex tachycardia. Dosage reduction may be necessary. There is limited experience with short-duration therapy with beta-blockers as a treatment for clevidipine -induced tachycardia; therefore, beta-blocker use for this purpose is not recommended. Close monitoring is recommended.

The calcium carbonate in Titralac has a major potential interaction with Malabsorption Syndrome.

Calcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.

Clevidipine has a major potential interaction with Pancreatitis.

Clevidipine is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.

The calcium carbonate in Titralac has a major potential interaction with Phosphate Imbalance.

Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. These complexes are eliminated in the feces. Clinical monitoring of serum calcium and phosphate concentrations is necessary.

The calcium carbonate in Titralac has a major potential interaction with Renal Dysfunction.

Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment. Hyperphosphatemia occurs during renal failure. Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure. Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.

The calcium carbonate in Titralac has a major potential interaction with Sarcoidosis.

Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis. Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma. Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.

Clevidipine has a moderate potential interaction with Tachyarrhythmia.

The use of clevidipine may produce systemic hypotension and reflex tachycardia. Dosage reduction may be necessary. There is limited experience with short-duration therapy with beta-blockers as a treatment for clevidipine -induced tachycardia; therefore, beta-blocker use for this purpose is not recommended. Close monitoring is recommended.